Ribbon Biolabs GmbH, a DNA synthesis company, has completed a EUR 18m Series A financing round led by Hadean Ventures with participation from, amongst others, Lansdowne Partners, Helicase Venture and existing investors IST cube and tecnet equity. A BRANDL TALOS-deal team led by Roman Rericha and Stephan Strass advised the lead investor, Hadean Ventures, on this financing round.
Ribbon Biolabs was founded in 2018 to redefine the potential of synthetic DNA. The funds will be used for the commercialization of the company’s DNA synthesis technology, which uses an innovative approach integrating combinatorial optimization algorithms to duie the automated enzymatic assembly of DNA. This includes the set-up of production facilities with key technology partners and the preparation for expansion into the US market.
» We are excited to support Ribbon Biolabs on its mission to fully automate long DNA synthesis. It was a pleasure working with Roman, Stephan and their team on this transaction and we look very much forward to many further projects with them. «
Walter Stockinger, Managing Partner at Hadean Ventures
The BRANDL TALOS-deal team was led by Roman Rericha and Stephan Strass and further consisted of Elena Ciresa and Céline Dobnikar. Ribbon Biolabs was advised by Herbst Kinsky (Carl Walderdorff and Christina Bernhart).